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ductivity and daily activities was assessed at study baseline, using the validated 
arthritis-specific Work Productivity Survey (WPS). Results: At baseline, pts had a 
mean age of 48 years and 55% were female; 61.6% had psoriasis skin involvement 
≥ 3% body surface area. 59.5% of pts were employed, 14.0% work disabled due to 
PsA, and 13.5% retired. Overall, a high burden of PsA on workplace and household 
productivity and on social activities was reported, with on average > 1 week (wk) of 
paid work affected and > 2 wks of household duties or social activities affected per 
month. Household productivity losses were on average, up to 2 to 3 times higher in 
non-employed or disease work disabled pts vs employed pts: on average household 
duties were affected 18 days or 26 days vs 10 days/month, respectively. Employed pts 
with manual jobs reported higher productivity losses at work and within the home 
vs those with non-manual jobs. Overall, 41.8% of pts required regular assistance 
from relatives, friends or paid caregivers in their usual activities because of PsA. 
These pts reported on average 2 to 3 times higher workplace and household produc-
tivity losses vs pts who did not require help. ConClusions: PsA is associated with 
a high burden of disease on workplace and household productivity that could lead 
to large financial burden for pts and society. Effective PsA treatments are needed 
to prevent disability and work losses, and reduce economic burden of the disease.
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objeCtives: To estimate the economic burden of axial spondyloarthritis (axSpA) and 
directly compare ankylosing spondylitis (AS) and axSpA with no definitive sacroiliitis 
on X-ray (non-radiographic axSpA, nr-axSpA) in terms of workplace and household 
productivity losses. Methods: The ongoing Phase 3 RAPID-axSpA trial (NCT01087762) 
recruited patients (pts) with adult-onset active axSpA according to ASAS criteria, and 
included AS and nr-axSpA pts. The impact of axSpA on workplace and household 
productivity was assessed at study baseline (BL), using the arthritis-specific Work 
Productivity Survey (WPS). Results: At BL, 69.2% of axSpA, 67.4% AS and 71.4% nr-
axSpA pts were employed outside the home. A high burden of axSpA on workplace and 
household productivity and on social activities was reported, with slightly higher burden 
in nr-axSpA vs AS pts. More AS vs nr-axSpA pts were unable to work (15.7% vs 8.2%). On 
average, axSpA pts reported > 1 wk of paid work and > 2 wks of household duties or social 
activities affected/month. Household productivity losses were up to 2–3 times higher in 
non-employed and disease work disabled vs employed pts. Employed pts with manual 
jobs reported higher losses at paid work and within household vs pts with non-manual 
jobs. 39.1% of axSpA pts required regular assistance in their usual activities (42.1% in 
AS vs. 35.4% in nr-axSpA) and reported higher workplace and household productivity 
losses vs those who did not require help. Similar patterns were observed in AS and nr-
axSpA. ConClusions: A similarly high burden of disease on workplace and household 
productivity was seen in AS and nr-axSpA pts that could lead to large financial burden 
for pts and society. Effective axSpA treatments are needed to prevent disability and work 
losses and to reduce the economic burden of axSpA.
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objeCtives: To assess loss of paid productivity in Polish rheumatoid arthritis (RA) 
patients according to disease activity and disability. Methods: We conducted a 
prospective one-center observational study with 6-month time horizon. The sample 
consisted of 109 RA patients of working age (women:< 60 years; men:< 65 years), 
stratified according to Disease Activity Score (DAS28-CRP) and disability index of 
the Health Assessment Questionnaire (HAQ-DI). Productivity loss was expressed 
by absenteeism and employment status changes: reduced work hours (part-time), 
unemployed and/or early retirement due to RA. Spearman rang correlation coef-
ficient test was used to investigate the relationship of productivity loss with disease 
activity and disability. Results: Patients were on average 48.5 years of age, had a 
mean disease duration of 8.5 years, and 85% were female. DAS28-CRP was ≤ 5.1 in 
52 patients (group A) and > 5.1 in 57 patients (group B). HAQ-DI was > 2 in 22 patients 
(group I), > 1 and ≤ 2 in 54 patients (group II), ≤ 1 in 33 patients (group III). Number of 
patients who lost productivity was 94 (86%) (79% in A vs. 93% in B, 100%, 94% and 
63.6% in I, II and III, respectively). Of them 63 (58%) patients received disability pen-
sion due to RA (48% in A vs. 67% in B, 77%, 76% and 15% in I, II and III, respectively). 
Mean number of working days lost was 120.7 (97.2 in A vs. 142.9 in B; 157.3, 143.1 
and 59.8 in I, II and III, respectively). Proportion of patients with productivity loss 
and number of working days lost were correlated with disease activity (p< 0.01 
and p< 0.001, respectively) and disability index (both p< 0.001). ConClusions: This 
study indicates high impact of disease activity and disability on productivity loss 
in RA patients. Treatment aiming at reducing disease activity decreases disability 
progress and may enhance productivity in Polish patients with RA.
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objeCtives: To assess transportation needs and number of home visits in rela-
tion to disease activity (DAS-28CRP) and disability index of the Health Assessment 
Questionnaire (HAQ-DI) in Polish patients with rheumatoid arthritis (RA) Methods: 
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objeCtives: Until recently, large-scale head-to-head randomized clinical trials (RCT) 
involving biologic drugs in the treatment of rheumatoid arthritis (RA) have been lack-
ing. In addition, most evidence of biologic RA treatments has relied on combination 
treatment with methotrexate. The RCT ADACTA compared adalimumab vs. tocili-
zumab monotherapies as the 1st biologic treatments for severe RA, and demonstrated 
tozilizumab’s clinical superiority over adalimumab. Based on this evidence, we assess 
the cost-utility of adalimumab and tocilizumab monotherapy in RA after the failure 
of traditional disease modifying antirheumatic drug(s) (tDMARD). Methods: Two 
sequences, namely adalimumab or tocilizumab followed by etanercept followed by 
best supportive care (BSC) including tDMARDs, were implemented in a probabilistic, 
individual sampling (microsimulation model) setting in order to compare the results 
among 1,230 Finnish RA patients in a lifetime scenario (based on the Finnish social 
insurance institution reimbursement data, 1,230 [42.6%] of anti-TNF users purchased 
anti-TNF without tDMARD in 2012). Clinical outcomes (no ACR20, ACR20, ACR50 and 
ACR70 responses, and their impact on Health Assessment Questionnaire, HAQ) were 
obtained from ADACTA and drug survivals from literature. HAQ-scores were linked 
non-linearly to EQ-5D scores based on the tocilizumab trials, and to hospitaliza-
tions and lost production days through literature data. All resources were valued 
with Finnish unit costs (drugs 4/2013, other costs 2012 real value). Analyses were 
performed from the Finnish payer perspective (excluding productivity loss) and 
societal perspective including 3% annual discount rate. Results: A QALY gained 
with the tocilizumab sequence costs € 14,294 (€ 9,111) compared with the adalimumab 
sequence from the payer (societal) perspective. The respective expected value of per-
fect information (EVPI) for the payer was € 996/patient. Population EVPI was € 121,770 
with € 20,000/QALY gained. According to cost-effectiveness acceptability frontier, the 
tocilizumab sequence had 89% probability for cost-effectiveness at € 20,000/QALY 
gained. ConClusions: After tDMARD(s) failure, tocilizumab monotherapy was cost-
effective in comparison to adalimumab monotherapy.
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objeCtives: Poor information on long term outcomes and costs on Tumor Necrosis 
Factor-α (TNF-α ) inhibitors in Psoriatic Arthritis (PsA) are available. Our aim was 
to evaluate long-term costs, benefits and cost-effectiveness of TNF-α inhibitors in 
PsA patients with inadequate response to conventional treatment with traditional 
disease-modifying antirheumatic drugs (DMARDs). Methods: A total of 55 of the 
107 enrolled patients included in the study at one year, completed the 5 years follow 
up period (2005-2010). Patients aged older than 18 years, with different forms of PsA 
and failure or intolerance to DMARDs therapy were treated with anti-TNF agents. 
Information on resource use, quality of life, disease activity, function and laboratory 
values were collected at baseline and through the 5 years of therapy. Costs (expressed 
in Euro 2011) and utility (measured by EQ-5D instrument) before and after TNF-α 
inhibitorstherapy were compared in order to estimate the incremental cost per qual-
ity adjusted life year (QALY) gained. The cost-effectiveness acceptability-curve was 
also calculated. Results: Thirty-four patients were males (61.8%), aged mean(SD)= 
48.94(11.09) years. The majority of patients (83.6%) had a predominant or exclusive 
peripheral arthritis. At the end of the 5 years, there was a significant increase in direct 
costs due to an increase of drug cost caused by TNF-α inhibitors that was partially 
offset by the decrease in indirect costs. The incremental cost estimated and the util-
ity gained of 0.22 gave an incremental cost-effectiveness ratio of 39,678.6 € per QALY 
gained for the society. The acceptability curve showed there would be a 90% likeli-
hood that anti-TNF therapy would be considered cost-effective at willingness-to-pay 
threshold of € 60,000 per QALY gained. ConClusions: Cost-effectiveness ratios are 
within the commonly accepted Italian willingness-to-pay threshold. These results 
show how TNF-α inhibitors could be long-term cost-effectiveness treatment. Our 
results need to be confirmed in larger samples of patients.
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objeCtives: To estimate the economic burden of moderate to severe psoriatic 
arthritis (PsA) on workplace and household productivity using data from RAPID-
PsA. Methods: The ongoing Phase 3 RAPID-PsA trial (NCT01087788) recruited 
patients (pts) with active PsA. Impact of PsA on workplace and household pro-
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objeCtives: Compliance to osteoporosis drugs is frequently very low, leading to 
an increased fracture risk. We investigated the factors associated with fracture 
risk in women with postmenopausal osteoporosis (PMO) in Hungary, with a focus 
on compliance. Methods: This retrospective analysis of data from the National 
Health Insurance Fund Administration included women aged ≥ 50 years with a 
diagnosis of osteoporosis (ICD-10 codes, M80 or 81), who started an osteoporosis 
drug prescription between Jan 2004–Dec 2012 (index event) and had a 13-month 
non-treatment period prior to this prescription. The relationship between all 
factors (covariates) and fracture risk was assessed using a dynamic Cox regres-
sion model and Andersen-Gill analysis, estimating 95% confidence intervals. 
Compliance was measured using the medication possession ratio (MPR); MPR≥ 80% 
at 1 year was considered compliant. Results: A total of 181,239 patients matched 
the inclusion criteria; 40.4% of patients were > 70 years old and 12.2% had prior 
fractures in the 36-month period before each index date. Compliant patients had a 
35% (RR= 0.65, CI= 0.59-0.72) fracture risk reduction versus non-compliant patients. 
Patients aged 70-79 years, and > 80 years, had an increased fracture risk of 71% 
(RR= 1.71, CI= 1.54-1.90) and 118% (RR= 2.18, CI= 1.94-2.46), respectively, compared 
to patients aged 50-60 years. Prior fractures were associated with a 32% increased 
risk of one new fracture (RR= 1.32, CI= 1.18-1.49), and with a 90% increased fracture 
risk (RR= 1.90, CI= 1.64-2.19) in patients with 2+ prior fractures, respectively, com-
pared to patients with no prior fractures. There was also a relationship between 
any co-medication and fracture risk, with a 12% (RR= 1.12, CI= 1.03-1.22) increase 
with one co-medication and an 11% (RR= 1.11, CI= 1.01-1.21) increase with 2+ co-
medications compared to none. ConClusions: Compliance was associated with 
protection against fracture (reduction of relative fracture risk). However, age, any 
co-medication and prior fractures were associated with an increased relative risk 
of fracture.
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objeCtives: Persistence to orally and/or frequently administered osteoporosis 
treatments is poor. Indeed, previous retrospective research has shown that approx-
imately 50% of patients discontinue oral treatments within one year. Denosumab 
is administrated as a treatment for postmenopausal osteoporosis (PMO) via a sub-
cutaneous injection once every 6 months, and better persistence with denosumab 
has been shown in randomized trials. The current study estimated treatment 
persistence among women initiating denosumab for PMO in Sweden. Methods: 
The study included post-menopausal women who initiated denosumab between 
May 2010 and July 2012 in the Swedish National Prescription Register. One injection 
of denosumab was defined as 6 months of persistence. Patients were considered 
persistent for an additional 6 months if they filled their next denosumab prescrip-
tion within 6 months + 56 days (permissible gap). Subgroup analyses included 
comparisons of pre-treated vs. treatment-naïve patients to other osteoporosis 
treatments, and of patients initiating denosumab treatment in 2010/2011 vs. 
2012. Results: The study identified 2,315 incident users of denosumab. Mean (SD) 
age was 73.7 (9.0) years and 60.7% were pre-treated. 83% (CI95:81-84) of patients 
were persistent at 12 months, 69% (CI95:67-71) at 18 months and 62% (CI95:60-65) at 
24 months. Increasing the permissible gap to 90 or 180 days resulted in 12-month-
persistence of 85% and 91%, respectively. Pre-treated patients were more persistent 
than treatment-naïve patients after 18 (71% vs. 67%) and 24 months (65% vs. 58%), 
but not at 12 months. No difference was observed between patients starting their 
treatment during 2010/2011 and 2012. ConClusions: Among Swedish women 
with PMO, persistence to denosumab treatment is high, and pre-treated patients 
are more persistent than treatment-naïve patients. Given the poor persistence to 
oral osteoporosis treatments, denosumab treatment could, in these patients, be 
considered a relevant alternative to increases persistence and hence optimizes 
outcomes in PMO.
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objeCtives: Persistence and compliance with prescribed medication are 
important factors in treatment success. This study calculated persistence and 
compliance to treatment among postmenopausal women with osteoporosis in 
Hungary. Methods: This retrospective analysis of data from the National Health 
Insurance Fund Administration included women aged ≥ 50 years with a diagnosis 
of osteoporosis (ICD-10 codes, M80 or 81), who started an osteoporosis prescription 
(including bisphosphonates, strontium ranelate, hormone replacement therapy, 
parathormone and denosumab) between January 2004 to December 2012. We esti-
mated 12- and 24-month persistence per active substance and administration type, 
with an 8-week grace period; and measured compliance using the medication pos-
session ratio (MPR; MPR≥ 80% at 12-months considered compliant). Results: A 
total of 288,194 patients matched the inclusion criteria;43.8% were aged > 70 years 
and 6.6% had prior fractures at first index date; 84.4% and 3.1% were receiving 
oral and intravenous bisphosphonates, respectively, and 12.5% other osteoporosis 
therapies. 12-month persistence to oral and injectable drugs was 31% and 76%, 
respectively. 12-month persistence was lowest for daily (23%) and monthly (27%) 
versus quarterly (58%) and half-yearly (84%) administration (100% persistence and 
compliance assumed for yearly administration), declining at 24 months to 10%, 
10%, 36% and 44% for daily, monthly, quarterly and yearly drugs, respectively (24-
month persistence to half-yearly drugs not available). Only 46% of patients were 
compliant with treatment, with compliance higher for injectable (daily, quarterly, 
Prospective data on distance covered due to RA (paid and non-paid, self and car-
egiver’s transport) and about number of medical home visits were gathered during 
6 months observation after discharge of non-selected RA patients from one tertiary 
academic hospital. Patients were stratified according to their DAS28-CRP and HAQ-DI. 
Spearman rang correlation coefficient test was used for statistical analysis. Results: 
A total of 205 consecutive RA patients included into the study were stratified in 5 
groups: A: DAS-28CRP ≤ 5.1 (89 patients), B: DAS28-CRP > 5.1 (116 patients), I: HAQ-DI 
≤ 1 (51 patients), II: HAQ-DI ≤ 2 and > 1 (88 patients) and III: HAQ-DI > 2 (66 patients). 
In the whole study group 157 (77%) patients used transport for a mean distance of 
461 kilometers in 6 months. Corresponding values for group A, B, I, II and III were 
as follows: 67% for 329 km, 84% for 563 km in B, 55% for 159 km in I, 81% for 528 km 
in II and 88% for 605 km in III. 7 patients used home visits (3% for a mean number 
of 0.1 visits - 2% for 0.2, 4% for 0.2, 0% for 0, 1% for 0.3 and 9% for 0.3 in A, B, I, II and 
III, respectively). There was significant positive correlation between disability and 
both proportion of patients using transport and distance covered (both p< 0.0001), 
between disability and home visits and between disease activity and transport (both 
p< 0.01). ConClusions: Problems with moving around and need for travelling due to 
the disease result in significant resource use in RA patients. Comprehensive services 
meeting these needs may diminish the burden of disease in Poland.
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objeCtives: To assess informal care use in relation to disease activity (DAS-28CRP) 
and disability index of the Health Assessment Questionnaire (HAQ-DI) in Polish 
patients with rheumatoid arthritis (RA). Methods: Data on amount of time con-
sumed for informal care (unpaid assistance of family member or other caregiver) 
was collected during a prospective one center cohort observational study of non-
selected RA patients discharged from tertiary academic hospital. At enrollment 
patients were divided according to DAS28-CRP and HAQ-DI. Observational period 
was 6 months. Spearman rang correlation coefficient test was used to investigate 
the relationship between informal care and disability. Results: A total of 205 
patients were included in the analysis: 89 with DAS-28CRP ≤ 5.1 (group A), 116 with 
DAS28-CRP > 5.1 (group B), 51 with HAQ-DI ≤ 1 (group I), 88 - with HAQ-DI ≤ 2 and > 1 
(group II) and 66 patients with HAQ-DI > 2 (group III). 164 (80%) patients have been 
looked after by informal caregivers (64% and 92% in A and B, respectively, and 47%, 
89% and 94% in I, II and III, respectively). Mean number of hours of informal care per 
patient during 6 months was 467 (336, 567, 153, 412 and 783 hours in A, B, I, II and 
III, respectively). There were significant (p< 0.0001) positive correlations between 
both disease activity and disability index and both number of patients being looked 
after by informal caregivers and number of hours of informal care. ConClusions: 
Informal care involves substantial time inputs depending on disease activity and 
functional status of the care receiving RA patients. On one side, improving access to 
formal caregiving might be a good solution to improve quality of life and enhance 
productivity of present informal caregivers in Poland. On the other side slowing 
down the disease process might reduce the need of informal care for RA patients.
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objeCtives: Postmenopausal osteoporosis (PMO) leads to an increased risk of 
fractures, which in turn is associated with high resource utilisation. DEXA scans 
measure the patient’s bone mineral density and are an important tool in assess-
ing fracture risk. We aim to determine if the monitoring of PMO patients using 
DEXA scans is associated with lower incidence of fracture. Methods: Analysis 
was undertaken using data from the 2012 Adelphi Osteoporosis Disease Specific 
Programme (DSP), a cross-sectional survey of patients with osteoporosis across the 
EU5 and the US. Physicians completed a detailed patient record form (PRF) for the 
next 10 consulting osteoporosis patients. The PRF captured patient information 
which included age, BMI and physician-perceived severity of the patient’s osteo-
porosis as well information on fracture history, DEXA scans received and date of 
diagnosis. Bootstrapped survival time regression using an exponential distribu-
tion on time to fracture was used to determine the hazard ratio (relative fracture 
risk) for those that had received a DEXA scan, compared with those that had not. 
Other covariates in the model were age, BMI, severity, and the possibility that the 
likelihood of a DEXA scan increases with duration of time since diagnosis. Results: 
Of the 2508 PMO patients with complete information required for the analysis, 1107 
had received a DEXA scan (and had associated treatment intervention) and 1401 
had received no DEXA scan. Patients who had received a DEXA scan had 59% (0.594, 
p= 0.006) of the fracture risk of those who had received no DEXA scan, adjusted by 
possible confounders (ceteris paribus). ConClusions: Patients tested with DEXA 
scans were associated with a significantly lower risk of fracture than those patients 
who were not. Over time increased use of DEXA testing could lead to a reduction in 
fractures and subsequently lower resource use and disease burden.
MuSculAr-SkElEtAl diSordErS – Patient-reported outcomes & Patient 
Preference Studies
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